Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

140.99 +0.19 (+0.13%)
Official Closing Price Updated: 7:00 PM EDT, Jun 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,205,594
Open 141.51
Bid (Size) 140.79 (1)
Ask (Size) 141.60 (2)
Prev. Close 140.80
Today's Range 140.81 - 143.59
52wk Range 75.56 - 144.50
Shares Outstanding N/A
Dividend Yield 1.25%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover. 
Via Benzinga
Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions
Eli Lilly & Co has intensified its fight against counterfeit versions of its popular obesity drug, Zepbound, by initiating additional legal proceedings against companies selling compounded versions of... 
Via Benzinga

Performance

YTD
+38.08%
+38.08%
1 Month
+4.31%
+4.31%
3 Month
+8.60%
+8.60%
6 Month
+36.25%
+36.25%
1 Year
+75.64%
+75.64%

More News

Read More
7 Stocks With Impressive Earnings Growth: Real or Engineered?
Via InvestorPlace
Eli Lilly Hits All-Time High, Named To Big Cap 20 List: Check These Lists For Best Stocks To Buy
Via Investor's Business Daily
3 Mega Cap Stock Bargains As Markets Hit All-Time Highs
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today
Via Benzinga
Novo Nordisk Unusual Options Activity For June 13
Via Benzinga
Obesity In Children - US Parents Face Tough Time To Access Recommended Treatment, Though Novo Nordisk's Drug Still Sees Strong Demand
Via Benzinga
The Best Biotech Stock to Invest $1,000 in Right Now
Via The Motley Fool
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
Via Investor's Business Daily
Could Structure Therapeutics Become the Next Novo Nordisk?
Via The Motley Fool
3 Best Stocks to Buy From the Fantastic 5
Via InvestorPlace
Week Of June 16: What's In Store For The Markets
Via Talk Markets
Where Will Madrigal Pharmaceuticals Be in 3 Years?
Via The Motley Fool
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Via The Motley Fool
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
Via Investor's Business Daily
7 A-Rated Biotech Stocks Worth Betting on in June
Via InvestorPlace
3 Stocks to Sell as Ozempic Surges in Popularity
Via InvestorPlace
Got $200? 2 Healthcare Stocks to Buy and Hold Forever.
Via The Motley Fool
Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug
Via The Motley Fool
Weight Loss Drugs: Are They Really Magic?
Via The Motley Fool
JPMorgan's $500M Venture Capital Fund Bets Big On Weight-Loss Drugs: 'They're All The Rage'
Via Benzinga
3 Stocks to Buy as Ozempic Surges in Popularity
Via InvestorPlace
Ozempic Maker Novo Nordisk Closes In On Lego As Denmark's Most Valuable Brand: Report
Via Benzinga
Humans Clamor For Weight Loss Drugs, But The Next Users Could Be... Pets?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.